Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Vunakizumab + Chemo in ES-SCLC
NCT07069270Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of vunakizumab in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07069270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069270.